Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — PhRMA, the eminent lobbying group for the pharmaceutical industry, spent more than $27.5 million on its lobbying activities in 2018 — the most the group has ever spent on lobbying in a single year.

The tally, as detailed in lobbying filings posted online on Tuesday, far outstrips the group’s previous record-setting spend, when it dropped a little more than $25 million in 2009, as Congress was deep in the debate over the Affordable Care Act. It spent just shy of that figure again in 2017.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Trump administration escalates its efforts to bring drug prices down

    That’s hilarious! There is none in there having any genuine interest in doing so. Other then, possibly hoping to gain consensus with voters. But mainly, pretending to change something, while keeping things the way they are to please their lobbyists donors and the real entities they care to benefit, pharma companies

Comments are closed.